vs
Side-by-side financial comparison of Coherus Oncology, Inc. (CHRS) and FrontView REIT, Inc. (FVR). Click either name above to swap in a different company.
FrontView REIT, Inc. is the larger business by last-quarter revenue ($18.2M vs $12.7M, roughly 1.4× Coherus Oncology, Inc.). FrontView REIT, Inc. runs the higher net margin — 2.2% vs -295.3%, a 297.5% gap on every dollar of revenue. On growth, Coherus Oncology, Inc. posted the faster year-over-year revenue change (64.9% vs 12.0%).
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
CHRS vs FVR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $12.7M | $18.2M |
| Net Profit | $-37.6M | $400.0K |
| Gross Margin | 68.3% | — |
| Operating Margin | -359.9% | 24.9% |
| Net Margin | -295.3% | 2.2% |
| Revenue YoY | 64.9% | 12.0% |
| Net Profit YoY | 25.7% | — |
| EPS (diluted) | $-0.34 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $18.2M | ||
| Q4 25 | $12.7M | $16.5M | ||
| Q3 25 | $11.6M | $16.8M | ||
| Q2 25 | $10.3M | $17.6M | ||
| Q1 25 | — | $16.2M | ||
| Q3 24 | — | $14.5M | ||
| Q2 24 | $10.3M | — | ||
| Q3 23 | $74.6M | — |
| Q1 26 | — | $400.0K | ||
| Q4 25 | $-37.6M | $-4.1M | ||
| Q3 25 | $-35.5M | $4.0M | ||
| Q2 25 | $297.8M | $-2.9M | ||
| Q1 25 | — | $-833.0K | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | $-12.9M | — | ||
| Q3 23 | $-39.6M | — |
| Q1 26 | — | — | ||
| Q4 25 | 68.3% | — | ||
| Q3 25 | 67.8% | — | ||
| Q2 25 | 66.9% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 82.4% | — | ||
| Q3 23 | 56.1% | — |
| Q1 26 | — | 24.9% | ||
| Q4 25 | -359.9% | — | ||
| Q3 25 | -383.1% | — | ||
| Q2 25 | -443.6% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -384.9% | — | ||
| Q3 23 | -42.9% | — |
| Q1 26 | — | 2.2% | ||
| Q4 25 | -295.3% | -24.9% | ||
| Q3 25 | -307.1% | 23.9% | ||
| Q2 25 | 2903.9% | -16.5% | ||
| Q1 25 | — | -5.1% | ||
| Q3 24 | — | -16.7% | ||
| Q2 24 | -125.5% | — | ||
| Q3 23 | -53.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | $-0.34 | $-0.19 | ||
| Q3 25 | $-0.31 | $0.19 | ||
| Q2 25 | $2.57 | $-0.16 | ||
| Q1 25 | — | $-0.06 | ||
| Q3 24 | — | — | ||
| Q2 24 | $-0.11 | — | ||
| Q3 23 | $-0.41 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.1M | $9.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $61.0M | $514.2M |
| Total Assets | $258.3M | $869.8M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $9.3M | ||
| Q4 25 | $172.1M | $13.5M | ||
| Q3 25 | $191.7M | $19.6M | ||
| Q2 25 | $237.6M | $8.4M | ||
| Q1 25 | — | $3.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | $159.2M | — | ||
| Q3 23 | $131.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $314.3M | ||
| Q3 25 | — | $307.1M | ||
| Q2 25 | — | $316.9M | ||
| Q1 25 | — | $310.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — |
| Q1 26 | — | $514.2M | ||
| Q4 25 | $61.0M | $391.2M | ||
| Q3 25 | $87.8M | $385.2M | ||
| Q2 25 | $119.8M | $369.9M | ||
| Q1 25 | — | $324.7M | ||
| Q3 24 | — | $1.0K | ||
| Q2 24 | $-84.1M | — | ||
| Q3 23 | $-133.6M | — |
| Q1 26 | — | $869.8M | ||
| Q4 25 | $258.3M | $854.4M | ||
| Q3 25 | $516.5M | $846.8M | ||
| Q2 25 | $439.5M | $856.5M | ||
| Q1 25 | — | $860.8M | ||
| Q3 24 | — | $1.0K | ||
| Q2 24 | $674.9M | — | ||
| Q3 23 | $583.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.80× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 0.96× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-19.7M | $42.1M | ||
| Q3 25 | $-46.3M | $8.3M | ||
| Q2 25 | $-46.6M | $9.3M | ||
| Q1 25 | — | $8.1M | ||
| Q3 24 | — | — | ||
| Q2 24 | $59.7M | — | ||
| Q3 23 | $-54.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | 0.0% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q3 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
FVR
Segment breakdown not available.
